Remebot Surgical Robot Secures RMB 130 Million Series C Funding to Advance Neurosurgical Robotics Innovation

VCBeat (WeChat ID: vcbeat) has learned that Beijing Baihui Weikang Technology Co., Ltd. (“Baihui Weikang”) recently announced the completion of its C-round financing of RMB 130 million, exclusively invested by the Zhejiang Zhuji Lianchuang Yongjun Medical Device Fund.Previously, the company secured nearly RMB 100 million in investment from institutions such as Yarui Capital, ZhenFund, Haiquan Fund, and Puhua Capital. This round of financing will be primarily allocated to the market promotion of its neurosurgical robotic system and the research and development of its other surgical robot product lines.

Founded in 2010, Baihui Weikang is a high-tech company specializing in the research and development, manufacturing, sales, and operation of medical robots. The company has obtained eight invention patents in relevant fields, along with more than ten software copyrights and other patents. Leveraging 18 years of technological accumulation, 15 years of clinical exploration, over 20,000 clinical surgeries, and six product iterations, the company launched the new-generation Remebot (“Ruimi”) neurosurgical robot in 2015.

As the first and only domestically produced neurosurgical surgical robot in China to receive CFDA certification, “Ruimi” can assist physicians in performing minimally invasive, precise, and efficient surgical procedures.The entire procedure takes an average of approximately 30 minutes, with a localization accuracy of 1 mm and an incision size of only 2 mm. It is currently widely used in nearly 100 types of neurosurgical conditions, including intracranial biopsy, cerebral hemorrhage, Parkinson’s disease, and epilepsy.

Since its inception, Huiwei Kang has adhered to the principles of being guided by clinical needs and independently developing core technologies, collaborating with experts to continuously refine its products. In July this year, under the guidance of Professor Zhang Jianguo’s team at Beijing Tiantan Hospital, “Ruimi” successfully performed a Deep Brain Stimulation (DBS) surgery—the procedure with the highest precision requirements in functional neurosurgery—marking that its performance metrics have reached international first-class standards.

“Ruimi” Assists Director Zhang Jianguo of Tiantan Hospital in Completing DBS Surgery

In addition to top-tier domestic Grade IIIA hospitals such as Tiantan Hospital, Xuanwu Hospital, PLA General Hospital (301), and Peking Union Medical College Hospital, “Ruimi” rapidly gained approval and was subsequently adopted by leading provincial hospitals, including the First Hospital of China Medical University and Qilu Hospital of Shandong University. By year-end, “Ruimi” is expected to have successfully facilitated robot-assisted minimally invasive surgeries at more than 30 hospitals.

Leveraging these renowned hospitals and experts, the company plans to make significant strides in telemedicine. Experts will guide local physicians through remote consultations, enabling them to perform treatments for basic conditions such as cerebral hemorrhage with robotic assistance. This initiative aims to alleviate, to some extent, the shortage of medical resources in certain regions.

The Lianchuang Yongjun Medical Fund, the investor in this round, was jointly established by the renowned private equity firm Shanghai Lianchuang Yongjun Equity Investment Management Co., Ltd. and first-class institutional investors including Shanghai Electric (a Fortune Global 500 manufacturing company), PICC, Shanghai Port & Shipping Investment, and the Zhuji Government Guidance Fund of Zhejiang Province. The fund primarily invests in medical equipment and devices, aiming to advance Shanghai Electric’s strategic layout in the medical device industry.

Regarding this round of financing, Baihui Weikang officially stated: “The introduction of strategic shareholders will help the company gain greater support in the manufacturing of high-end, precision equipment and in financial innovation. We also look forward to generating even greater synergy between both parties in the future. Meanwhile, Baihui Weikang will continue to make persistent efforts, deepen its expertise in the field of surgical robots, benefit patients, and become a leading enterprise in China and around the world.”